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Abstract
Backgorund: Mixed hyperlipidemia is common in patients with diabetes. Statins, the choice drugs,
are effective at reducing lipoproteins that contain apolipoprotein B100, but they fail to exert good
control over intestinal lipoproteins, which have an atherogenic potential. We describe the effect of
prescription omega 3 fatty acids on the intestinal lipoproteins in patients with type 2 diabetes who
were already receiving fluvastatin 80 mg per day.
Methods: Patients with type 2 diabetes and mixed hyperlipidemia were recruited. Fasting lipid
profile was taken when patients were treated with diet, diet plus 80 mg of fluvastatin and diet plus
fluvastatin 80 mg and 4 g of prescription omega 3 fatty acids. The intestinal lipoproteins were
quantified by the fasting concentration of apolipoprotein B48 using a commercial ELISA.
Results: The addition of 4 g of prescription omega 3 was followed by significant reductions in the
levels of triglycerides, VLDL triglycerides and the triglyceride/HDL cholesterol ratio, and an
increase in HDL cholesterol (P < 0.05). Fluvastatin induced a reduction of 26% in B100 (P < 0.05)
and 14% in B48 (NS). However, the addition of omega 3 fatty acids enhanced this reduction to 32%
in B100 (NS) and up to 36% in B48 (P < 0.05).
Conclusion: Our preliminary findings therefore suggest an additional benefit on postprandial
atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin.
Background
Type 2 diabetes is characterized by hypertriglyceridemia,
low concentrations of HDL cholesterol, increased small-
dense LDL (sdLDL), greater postprandial lipidemia and a
considerable increase in vascular risk [1]. It has been
clearly established that LDL cholesterol levels should be
kept below 100 mg/dL (with an optional goal of < 70 mg/
dL) or, if hypertriglyceridemia is present, a non-HDL cho-
lesterol < 130 mg/dL (optional < 100 mg/dL). Together
with dietary recommendations and lifestyle changes, stat-
ins are the drugs of choice for this goal [2].
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Postprandial lipoprotein particles have been shown to be
atherogenic in experimental animal [3], case-control [4]
and histological studies [5]. Indeed, nonfasting triglycer-
ides predict the vascular risk better than fasting measure-
ments [6]. Additionally, postprandial triglycerides are
independently associated with carotid [7] and peripheral
atheromatosis [8] in patients with type 2 diabetes. Accord-
ingly, it seems reasonable to seek additional control of the
triglycerides in patients with mixed hyperlipidemia. We
therefore undertook a preliminary evaluation of the effect
of the addition of omega 3 fatty acids on the postprandial
particles, measured specifically as plasma concentrations
of apolipoprotein B48, in diabetic patients with mixed
hyperlipidemia receiving treatment with fluvastatin.
Patients and methods
We undertook a non-controlled, open-label study of the
lipid effects of omega 3 fatty acids when they were added
to a low-calorie diet and fluvastatin in patients with type
2 diabetes and mixed hyperlipidemia. The diabetic
patients, who had an acceptable metabolic control, were
selected from those who attended the Lipids Unit with
mixed hyperlipidemia. Patients were excluded if they had
known vascular disease or if they refused to participate.
The study was approved by the Ethics and Research Com-
mittee of the Virgen de la Victoria Hospital, Malaga.
The patients were seen on four occasions. The first visit
was to select and obtain the informed consent of the
patients. At this visit the patients were instructed to cease
taking any lipid-lowering treatment and instructed to fol-
low a low-calorie diet for six weeks. This diet was 600 kcal
below the basic calorie needs, as calculated by the Harris
and Benedict equation [9]. At the second visit, six weeks
after starting the low-calorie diet, a 12-hour fasting blood
sample was obtained and the patients were requested to
continue the diet advised and to take 1 prolonged-release
80 mg fluvastatin tablet at night until the end of the study.
At the third visit, eight weeks after starting the treatment
with fluvastatin 80 mg, a further blood sample was taken
and, in addition to the diet and the fluvastatin 80 mg, the
patients were asked to take 4 capsules of prescription
omega 3 fatty acids daily, containing 460 mg of EPA and
380 mg of DHA ethyl esters. The patients were examined
8 weeks later at the final visit. The clinical variables
assessed at each visit were weight, waist circumference,
blood pressure, degree of treatment compliance, adverse
effects and a subjective evaluation of the dietary compli-
ance.
Laboratory variables
After a 12-h overnight fast, a sample of blood was drawn
to measure levels of glycemia, glycated hemoglobin, insu-
lin, lipids and lipid fractions. Serum glucose was meas-
ured with a Cobas Integra (Roche) autoanalyzer, using a
hexokinase-based enzymatic method. The glycated hemo-
globin was measured by HPLC (ADAMS-A1c HA 8160).
The plasma lipids, cholesterol and triglycerides were
measured with enzymatic techniques (HORIBA-ABX,
Montpellier, France) in a Cobas Mira autoanalyzer. Lipo-
proteins were separated by β quantitation (ultracentrifu-
gation) using the Lipid Research Clinics Protocol. The
levels of apolipoprotein B48 were quantified with a high-
sensitivity commercial ELISA (Shibayagi Co Ltd, Ishihara,
Japan). Plasma levels of apolipoproteins were measured
by immunoturbidimetry; A1 and B100 from Incstar, Dia-
sorin, Stillwater, OK, USA and C-II and C-III from Daichii
Pure Chemicals, Kyoto, Japan.
Statistical studies
The variables are shown as the mean ± SD. To compare the
changes in the different variables over the three study
points we used the Student t test for paired data, because
the normality assumption was confirmed for all the varia-
bles. The analysis was made with SPSS 15.0 (SPSS Inc,
Chicago, IL)
Results
The study initially included nine patients, but one with-
drew voluntarily at the start; the results therefore refer to
eight patients, five men and three women, aged 57 ± 5
years. Six patients were hypertensive and all were receiving
treatment with an angiotensin-converting enzyme (ACE)
inhibitor or an angiotensin receptor antagonist II (ARA-
II). No patient had experienced any cardiovascular event.
Three patients were treating their diabetes with diet,
another three with metformin, one with glycazide and
another with glycazide plus metformin. The low-calorie
diet, blood-pressure lowering treatment and antidiabetic
medication remained unchanged throughout the study
period.
Table 1 shows the clinical characteristics of the study
patients. All were overweight or obese and had adequate
glycemic control during the study period. Table 2 shows
the significant reduction in the levels of total cholesterol,
LDL cholesterol, apolipoprotein B100 and apolipopro-
tein C-III, and an increase in the C-II/C-III ratio two
months after starting treatment with fluvastatin. The addi-
tion of 4 g of prescription omega 3 fatty acids was fol-
lowed by a significant reduction in serum triglycerides,
VLDL triglycerides and the triglyceride/HDL cholesterol
ratio and a significant increase in HDL cholesterol. Apoli-
poprotein B48, the main outcome variable in this study,
only fell significantly after the addition of 4 g of omega 3
fatty acids to the statin treatment (Fig 1).
Discussion
Omega 3 fatty acids have long been used in the treatment
of hypertriglyceridemia, as they reduce the hepatic pro-Cardiovascular Diabetology 2009, 8:1 http://www.cardiab.com/content/8/1/1
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duction of VLDL, favor fatty acid oxidation and enhance
VLDL clearance [10]. They have also been shown to
reduce levels of chylomicrons and their remnants, as well
as the amount of apolipoprotein B48 [11]. The reduction
in the concentrations of triglycerides and VLDL triglycer-
ides and the increase in HDL cholesterol noted in this
study are thus in agreement with the literature mentioned.
Concerning LDL cholesterol, treatment with omega 3 fatty
acids in patients with hypertriglyceridemia or mixed
hyperlipidemia is usually followed by a slight rise in LDL
Table 1: Anthropometrical data, blood pressure and glycemic parameters.
(A) Diet (B) Diet plus Fluvastatin 80 mg (C) Diet plus Fluvastatin 80 mg plus Omacor 4 g
Weight (Kg) 79 ± 14 78 ± 15 78 ± 14
BMI (kg/mt2) 31.3 ± 3.5 30.8 ± 4.0 30.7 ± 3.8
Waist Circunference (cm) 106 ± 8 105 ± 10 105 ± 10
Glucose (mmol/L) 10.2 ± 3.2 10.8 ± 3.4 11.2 ± 2.8
HbA1c (%) 6.56 ± 0.75 6.56 ± 1.10 6.61 ± 1.16
Insulin (μU/ml) 15.4 ± 11.7 13.5 ± 8.0 14.2 ± 10.9
HOMA-IR 7.6 ± 7.4 7.1 ± 6.5 8.0 ± 8.3
All changes did not reach statistical significance
Table 2: Fasting lipids, lipoproteins and apolipoproteins in the three periods of treatment
(A) Diet (B) Diet plus Fluvastatin 80 mg (C) Diet plus Fluvastatin 80 mg plus Omacor 4 g
Total Cholesterolac 259 ± 55 174 ± 35 203 ± 54
LDL cholesterolac 157 ± 47 103 ± 25 127 ± 30
HDL cholesterolbc 34 ± 9 32 ± 10 40 ± 11
Non-HDL cholac 225 ± 55 142 ± 35 163 ± 54
Triglyceridesc 337 ± 153 263 ± 226 195 ± 129
VLDL triglyceridesc 289 ± 160 224 ± 222 136 ± 118
Tg/HDL-chol ratioc 4.80 ± 2.69 4.39 ± 5.10 2.23 ± 1.56
Apo A-1 113 ± 24 107 ± 41 124 ± 26
Apo B100ac 126 ± 34 89 ± 16 82 ± 16
Apo B48c 5.81 ± 2.59 4.12 ± 2.78 3.07 ± 1.47
Apo C-IIac 20.4 ± 6.1 18.1 ± 5.6 15.8 ± 6.8
Apo C-III a 18.7 ± 5.7 12.9 ± 3.5 12.8 ± 4.7
C-II/C-III ratio 1.13 ± 0.31 1.41 ± 0.29 1.30 ± 0.16
Data showed as mg/dL except apo B48, in mg/L.
a (A) vs (B) p < 0.05.
b (B) vs (C) p < 0.05.
c (A) vs (C) p < 0.05.Cardiovascular Diabetology 2009, 8:1 http://www.cardiab.com/content/8/1/1
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cholesterol [12]. Although in our study, LDL cholesterol
rose slightly, but not significantly after the omega 3 treat-
ment, the marked reduction in the triglyceride/HDL cho-
lesterol ratio noted suggests the transformation of sdLDL
to larger particles [13].
Evidence exists for the beneficial effect on non-HDL cho-
lesterol of the addition of omega 3 fatty acids to the treat-
ment in persons with residual hypertriglyceridemia
despite the use of statins [14]. However, their benefit on
the intestinal atherogenic lipoprotein particles has not
been assessed.
The quantification of apolipoprotein B48 by ELISA is a
simple way to measure postprandial metabolism, without
the need for ultracentrifugation, sample delipidation and
gradient electrophoresis, a very costly process. Apolipo-
protein B48 is specific for the intestinal lipoproteins [15]
and its fasting levels correlate very well with the area
under the curve after a fatty meal [16]. Its levels are raised
in persons with type 2 diabetes, especially when they also
have renal failure [17].
The effects of fluvastatin on the concentration of apolipo-
protein B48 has not been reported. Nevertheless, atorvas-
tatin is able to reduce apolipoprotein B48 concentrations
by increasing the catabolism of chylomicrons and their
remnants [18,19]. This study supports the hypothesis that
levels of B48-containing atherogenic lipoproteins may be
further reduced by omega 3 fatty acids, even when added
to the traditional statin therapy; in fact, the reduction in
the B48 was over two-fold greater with the omega 3 fatty
acids than with 80 mg of fluvastatin alone (Figure 1).
Because we just evaluated the patients over eight weeks,
the reduction in the levels of apolipoprotein B48 might be
even more pronounced over time.
The apolipoprotein B48 concentrations only fell signifi-
cantly after the incorporation of omega 3 fatty acids to the
treatment with fluvastatin. As treatment with omega 3
fatty acids in patients with hypercholesterolemia who are
receiving statins is accompanied by a reduction in
ischemic events and vascular death, even in populations
that have a high consumption of fish [20], we may specu-
late that the reduction in apolipoprotein B48-containing
Plasma levels of apolipoprotein B100 and apolipoprotein B48 according to treatment period Figure 1
Plasma levels of apolipoprotein B100 and apolipoprotein B48 according to treatment period. The reduction in 
apolipoprotein B100 was significant after adding fluvastatin 80 mg to the diet, whereas apolipoprotein B48 only fell significantly 
after the addition of 4 g of omega 3 fatty acids to the diet and the fluvastatin 80 mg.Cardiovascular Diabetology 2009, 8:1 http://www.cardiab.com/content/8/1/1
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particles might contribute to this benefit. It is believed
that omega 3 fatty acids enhances chylomicron clearence
due to a reduction in hepatic VLDL synthesis [11]. More-
over, in experimental models omega 3 fatty acids may also
reduce intestinal lipoprotein production [21], which is
increased in patients with insulin-resistance [22] and type
2 diabetes [23].
In conclusion, these preliminary findings suggest that
treatment with 4 g of omega 3 fatty acids added to higher
doses of fluvastatin in diabetic patients with mixed hyper-
lipidemia is accompanied by a significant additional ben-
efit in apolipoprotein B48-containing particles and may
thus represent a complementary therapy for the reduction
of LDL cholesterol, non-HDL cholesterol and B100 to that
achieved with statins alone. Nevertheless, due to small
sample size, lack of postprandial data and open-label
design, large-scale, double-blind, randomized studies are
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